NCT03851237View on ClinicalTrials.gov

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

64Cu-DOTA-ECLIi

-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i

DEVICE

PET/CT

-Standard of care

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER